ArticleJournal of Alzheimer's disease : JAD2017
A Critical Assessment of Research on Neurotransmitters in Alzheimer's Disease.
Article in Journal of Alzheimer's disease : JAD, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- The Association and Prognostic Implications of Long Non-Coding RNAs in Major Psychiatric Disorders, Alzheimer's Diseases and Parkinson's Diseases: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Circadian Disruption Through Light-Dark Cycle Alteration Induced Alzheimer's Disease-like Pathology in Mice.Biomolecules · 2026Article
- MicroRNA-502-3p Modulates the GABA A Subunits, Synaptic Proteins, and Mitochondrial Morphology in Hippocampal Neurons.Molecular neurobiology · 2025Article
- Data Mining Approach to Melatonin Treatment in Alzheimer's Disease: New Gene TargetsInternational journal of molecular sciences · 2025Article
- In silico metabolic modelling links microbiome-derived metabolites to risk factors of Alzheimer's disease.Gut microbes reports · 2025Article
- Uncovering atrophy progression pattern and mechanisms in individuals at risk of Alzheimer's disease.Brain communications · 2025Article
- Integrative metabolomics science in Alzheimer's disease: Relevance and future perspectives.Ageing research reviews · 2023Review
- State of the Art of microRNAs Signatures as Biomarkers and Therapeutic Targets in Parkinson's and Alzheimer's Diseases: A Systematic Review and Meta-Analysis.Biomedicines · 2023Review
- Proteomic analysis for the effects of non-saponin fraction with rich polysaccharide from Korean Red Ginseng on Alzheimer's disease in a mouse model.Journal of ginseng research · 2023Article
- Review
- Biological and therapeutic role of LSD1 in Alzheimer's diseases.Frontiers in pharmacology · 2022Review
- Neuronal ER-Signalosome Proteins as Early Biomarkers in Prodromal Alzheimer's Disease Independent of Amyloid-β Production and Tau Phosphorylation.Frontiers in molecular neuroscience · 2022Article
- Downregulation of PIK3CB Involved in Alzheimer's Disease via Apoptosis, Axon Guidance, and FoxO Signaling Pathway.Oxidative medicine and cellular longevity · 2022Article
- MissingGenes · 2021Review
- Bright Light Therapy in Older Adults with Moderate to Very Severe Dementia: Immediate Effects on Behavior, Mood, and Physiological Parameters.Healthcare (Basel, Switzerland) · 2021Article
- Regulation of Melatonin and Neurotransmission in Alzheimer's Disease.International journal of molecular sciences · 2021Review
- Molecular and Imaging Biomarkers in Alzheimer's Disease: A Focus on Recent Insights.Journal of personalized medicine · 2020Review
- The Role of Oxidant-Antioxidant Status in Suicide Behavior in Kurdish Ethnicity.Basic and clinical neuroscienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The purpose of this mini-forum, "Neurotransmitters and Alzheimer's Disease", is to critically assess the current status of neurotransmitters in Alzheimer's disease. Neurotransmitters are essential neurochemicals that maintain synaptic and cognitive functions in mammals, including humans, by sending signals across pre- to post-synaptic neurons. Authorities in the fields of synapses and neurotransmitters of Alzheimer's disease summarize the current status of basic biology of synapses and neurotransmitters, and also update the current status of clinical trials of neurotransmitters in Alzheimer's disease. This article discusses the prevalence, economic impact, and stages of Alzheimer's dementia in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.